Paul T. Kirschmeier

12.9k total citations · 2 hit papers
99 papers, 7.5k citations indexed

About

Paul T. Kirschmeier is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul T. Kirschmeier has authored 99 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 50 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul T. Kirschmeier's work include Cancer-related Molecular Pathways (28 papers), Protein Kinase Regulation and GTPase Signaling (26 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Paul T. Kirschmeier is often cited by papers focused on Cancer-related Molecular Pathways (28 papers), Protein Kinase Regulation and GTPase Signaling (26 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Paul T. Kirschmeier collaborates with scholars based in United States, United Kingdom and Japan. Paul T. Kirschmeier's co-authors include W. Robert Bishop, I. Bernard Weinstein, Linda James, Gerard M. Housey, Andrea Basso, Mark D. Johnson, Stuart Black, Joseph J. Catino, Asra Mirza and Jin-Keon Pai and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Paul T. Kirschmeier

96 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors

1997 706 citations Paul T. Kirschmeier, Linda James et al. Journal of Biological Chemistry profile →
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

2014 590 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Paul T. Kirschmeier

Since Specialization

Citations

This map shows the geographic impact of Paul T. Kirschmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul T. Kirschmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul T. Kirschmeier more than expected).

Fields of papers citing papers by Paul T. Kirschmeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul T. Kirschmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul T. Kirschmeier. The network helps show where Paul T. Kirschmeier may publish in the future.

Co-authorship network of co-authors of Paul T. Kirschmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Paul T. Kirschmeier. A scholar is included among the top collaborators of Paul T. Kirschmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul T. Kirschmeier. Paul T. Kirschmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition 2019 ·Clinical Cancer Research ·Kalindi Parmar, Bose Kochupurakkal, Jean‐Bernard Lazaro, Zhigang C. Wang, Sangeetha Palakurthi, Paul T. Kirschmeier, Chunyu Yang, Larissa A. Sambel, Anniina Färkkilä, Elizaveta Reznichenko, Hunter D. Reavis, Connor E. Dunn, Lee Zou, T. Khanh, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu, Alan D. D’Andrea, Geoffrey I. Shapiro	103
2	Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer 2018 ·Cancer Discovery ·Shunsuke Kitajima, Elena V. Ivanova, Sujuan Guo, Ryohei Yoshida, Marco Campisi, Shriram K. Sundararaman, Shoichiro Tange, Yoichiro Mitsuishi, Tran C. Thai, Sayuri Masuda, Brandon Piel, Lynette M. Sholl, Paul T. Kirschmeier, Cloud P. Paweletz, Hideo Watanabe, Mamiko Yajima, David A. Barbie	348
3	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing 2018 ·Cancer Immunology Research ·Patrick H. Lizotte, Ruey‐Long Hong, Troy A. Luster, Megan E. Cavanaugh, Luke J. Taus, Stephen Wang, (unknown), (unknown), Aaron Yang, Meghana Kulkarni, (unknown), (unknown), Hsiang‐Fong Kao, Mari Kuraguchi, Mark Bittinger, Paul T. Kirschmeier, Nathanael S. Gray, David A. Barbie, Pasi A. Jänne	69
4	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients 2015 ·Clinical Cancer Research ·Cloud P. Paweletz, Adrian G. Sacher, (unknown), Ryan S. Alden, Allison O’Connell, Stacy L. Mach, Yanan Kuang, Leena Gandhi, Paul T. Kirschmeier, Jessie M. English, Lee P. Lim, Pasi A. Jänne, Geoffrey R. Oxnard	177
5	Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA breakdown → 2014 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Stacy L. Mach, Allison O’Connell, Melissa M. Messineo, Jason J. Luke, Mohit Butaney, Paul T. Kirschmeier, David M. Jackman, Pasi A. Jänne	590
6	New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents 2014 ·Bioorganic & Medicinal Chemistry Letters ·Hugh Zhu, Jagdish Desai, Alan Cooper, James Wang, (unknown), Paul T. Kirschmeier, Corey Strickland, Ming Liu, Amin A. Nomeir, Viyyoor Girijavallabhan	6
7	A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies 2013 ·Journal of Translational Medicine ·John Nemunaitis, Karen Small, Paul T. Kirschmeier, Da Zhang, Yali Zhu, Ying‐Ming Jou, Paul Statkevich, Siu‐Long Yao, Rajat Bannerji	105
8	Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor 2013 ·Bioorganic & Medicinal Chemistry Letters ·Yongqi Deng, Gerald W. Shipps, Lianyun Zhao, M. Arshad Siddiqui, Janeta Popovici-Müller, (unknown), José S. Duca, Alan Hruza, Thierry Fischmann, Vincent Madison, Rumin Zhang, Charles McNemar, Todd Mayhood, Rosalinda Syto, (unknown), Paul T. Kirschmeier, Emma Lees, David Parry, William T. Windsor	17
9	Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor 2010 ·Molecular Cancer Therapeutics ·David Parry, Timothy J. Guzi, Fergus Shanahan, Nicole R. Davis, Deepa Prabhavalkar, Derek Wiswell, Wolfgang Seghezzi, Kamil Paruch, Michael P. Dwyer, Ronald J. Doll, Amin A. Nomeir, William T. Windsor, Thierry Fischmann, Yaolin Wang, Martin Oft, Taiying Chen, Paul T. Kirschmeier, Emma Lees	434
10	SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics 2010 ·Molecular Cancer Therapeutics ·Andrea Basso, Ming Liu, Chaoyang Dai, Kimberly Gray, (unknown), Seema Tevar, Suining Lee, Lianzhu Liang, A. S. Ponery, Bohdan Yaremko, Elizabeth Smith, Huadong Tang, Payal R. Sheth, M. Arshad Siddiqui, Daniel J. Hicklin, Paul T. Kirschmeier	17
11	An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach 2009 ·Toxicology ·(unknown), Harry R. Davis, Paul T. Kirschmeier, Diane Levitan, Ronald D. Snyder, Kimberley A. Treinen, J. S. Macdonald	21
12	SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models 2008 ·Cancer Research ·Yaolin Wang, Xiaoying Wang, Philip Lipari, (unknown), Ming Liu, Lingling Wu, Martin Oft, Satya Medicherla, David Parry, Emma Lees, Dan Hicklin, Paul T. Kirschmeier	1
13	Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo 2008 ·Gynecologic Oncology ·(unknown), (unknown), Gongjie Liu, (unknown), W. Robert Bishop, Paul T. Kirschmeier, Ming Liu, Brian J. Long	16
14	In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor 2007 ·Cancer Research ·David Parry, Timothy J. Guzi, Wolfgang Seghezzi, Kamil Paruch, Ronald J. Doll, Amin A. Nomeir, Yaolin Wang, Martin Oft, Paul T. Kirschmeier, Taiying Chen, Emma Lees	3
15	A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. 2000 ·PubMed ·Alex A. Adjei, Charles Erlichman, J. Nathan Davis, David L. Cutler, Jeff A. Sloan, Randolph S. Marks, Lorelei J. Hanson, Phyllis A. Svingen, Pamela J. Atherton, W. Robert Bishop, Paul T. Kirschmeier, Scott H. Kaufmann	201
16	Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules 2000 ·Journal of Biological Chemistry ·Hena R. Ashar, Linda James, Kimberly Gray, Donna Carr, Stuart Black, Lydia Armstrong, W. Robert Bishop, Paul T. Kirschmeier	261
17	Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity 1999 ·Bioorganic & Medicinal Chemistry ·F. George Njoroge, Bancha Vibulbhan, W. Robert Bishop, Paul T. Kirschmeier, (unknown), Amin A. Nomeir, Ming Liu, Ronald J. Doll, Viyyoor Girijavallabhan, Ashit K. Ganguly	3
18	Transduction of the Human Insulin Gene via Retroviral Vectors Fails to Yield Spliced Transcripts 1989 ·DNA ·Archibald S. Perkins, Paul T. Kirschmeier, I. Bernard Weinstein	4
19	Construction and Characterization of a Retroviral Vector Demonstrating Efficient Expression of Cloned cDNA Sequences 1988 ·DNA ·Paul T. Kirschmeier, Gerard M. Housey, Mark D. Johnson, Archibald S. Perkins, I. Bernard Weinstein	150
20	Role of protein kinase C in regulation of gene expression and relevance to tumor promotion. 1987 ·Environmental Health Perspectives ·Mark D. Johnson, Gerard M. Housey, C A O'Brian, Paul T. Kirschmeier, I. Bernard Weinstein	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact